Common and Rare Ovarian Cancer Metastasis Sites

Ovarian cancer spreads primarily within the abdominal cavity rather than through the bloodstream, making its metastatic pattern unusual compared to many other solid tumors. The omentum, the fatty apron of tissue draped over the intestines, is the single most common destination, but cancer cells also seed the peritoneal lining of the pelvis and abdomen, the diaphragm, and the surfaces of abdominal organs. In advanced disease, fluid buildup in the chest (pleural effusion) and, less frequently, true organ-level metastases to the liver, spleen, lungs, brain, or bone can occur. Understanding where ovarian cancer tends to land, and why, shapes everything from surgical planning to prognosis.

Why Ovarian Cancer Favors the Peritoneal Cavity

Most cancers spread by breaking into blood vessels or lymphatic channels, traveling to distant organs, and establishing new tumors there. Ovarian cancer can do this too, but its dominant route is different: cells shed directly from the ovary or fallopian tube into the peritoneal fluid that bathes the abdominal organs. This process, called transcoelomic dissemination, means that cancer cells float freely in the abdomen and settle on surfaces where conditions are favorable. Research using fluorescently labeled cell lines has shown that cells can detach from a primary tumor either individually or as small clusters, and those clusters survive far better than lone cells. Roughly four out of five cell clusters isolated from ascites fluid came from a single origin rather than from separate cells clumping together afterward, supporting the idea that the tumor sheds ready-made groups rather than assembling them on the fly.

Once free-floating, these cell clusters form spheroids, tiny balls of tumor cells suspended in peritoneal or ascites fluid. Immune cells called tumor-associated macrophages appear to help this process along. Research has found that macrophages physically embed themselves in the center of spheroids and secrete growth factors that promote tumor cell survival and proliferation while the spheroids drift toward new attachment sites.

The peritoneal fluid does not circulate randomly. It follows a predictable clockwise path driven by breathing and diaphragm movement, carrying detached cancer cells upward toward the diaphragm and rightward toward the omentum. This flow pattern explains why the omentum and the right diaphragm are such frequent targets.

The Omentum as a Preferred Landing Site

The omentum is essentially a sheet of fat and connective tissue hanging from the stomach and draping over the intestines. It is rich in adipocytes (fat cells), immune cells, and blood vessels, all of which make it a welcoming environment for arriving cancer cells. Proteomic and metabolomic profiling has shown that when ovarian cancer cells encounter omental fat cells, the cancer cells undergo dramatic metabolic rewiring. They ramp up lipid metabolism and upregulate a protein called FABP4, a lipid-transport molecule that helps them absorb fatty acids from surrounding adipocytes.

This metabolic shift does more than fuel tumor growth. It also contributes to chemotherapy resistance. Cancer cells that have taken up residence in the omentum and begun feeding on local fat stores become harder to kill with platinum-based drugs like carboplatin. This helps explain why omental disease, even when surgically removed, tends to recur and resist subsequent treatment rounds. For surgeons, removing the omentum (an omentectomy) is a standard part of cytoreductive surgery for ovarian cancer, even when the tissue looks grossly normal, because microscopic disease is so frequently present there.

Peritoneal Surfaces and Molecular Attachment

Beyond the omentum, cancer cells settle on peritoneal surfaces throughout the abdomen and pelvis. The peritoneum is a thin membrane lining the abdominal cavity and covering most organs, and its mesothelial cells are the first point of contact for floating tumor cells. Research has shown that one of the molecular keys to this process is a loss of E-cadherin, a protein that normally keeps cells stuck together. When ovarian cancer cells lose E-cadherin, they upregulate a different adhesion receptor that enhances their ability to attach to and invade the peritoneal lining.

⁴

Once attached, tumor cells begin transforming the mesothelial cells underneath them into cancer-associated fibroblasts through a process resembling a cellular identity change. Tiny vesicles called exosomes, released by the tumor, help orchestrate this transformation even before cancer cells physically arrive, essentially preparing the landing site in advance.

⁵⁶

Diaphragm Involvement

The diaphragm is one of the most clinically significant metastatic sites in advanced ovarian cancer. Because peritoneal fluid flows upward with each breath, cancer cells are carried directly to the undersurface of the diaphragm, especially on the right side. In a study of patients with stage III and IV disease, about two-thirds had diaphragmatic involvement, and when the overall burden of peritoneal disease was high, involvement was virtually universal.

⁷

Surgical data confirm this pattern. In one series of patients who underwent diaphragm resection during debulking surgery, about 85% of resected specimens contained malignant cells on pathology review, with only around 13% turning out to be tumor-free.

⁸

Diaphragmatic disease matters beyond staging. Tumor implants on the diaphragm can cause right-sided chest pain, referred shoulder pain, or difficulty breathing. They can also create pathways for fluid and even cancer cells to cross from the abdominal cavity into the chest, contributing to pleural effusions.

Pleural Effusions and Thoracic Spread

Among patients whose disease reaches beyond the peritoneal cavity, the most common finding is a malignant pleural effusion, fluid in the chest that contains cancer cells. A multicenter study of stage IV ovarian cancer found that malignant pleural effusion accounted for about 40% of all extraperitoneal disease.

⁹

Pleural effusions in ovarian cancer are usually right-sided, which is consistent with the rightward peritoneal fluid circulation and the communication between the abdomen and the right chest through tiny pores in the diaphragm. In a surgical series where patients underwent video-assisted thoracic surgery, about 59% had malignant pleural biopsies, and roughly three-quarters of pleural fluid samples tested positive for cancer cells.

¹⁰

An analysis of stage IV subtypes showed that pleural effusions were the most common form of distant disease, followed by parenchymal organ metastases and then extra-abdominal lymph node involvement.

¹¹

Liver Involvement, Surface Versus Deep

The liver is a frequent site of disease in advanced ovarian cancer, but the type of involvement matters enormously for prognosis. Most liver disease in ovarian cancer is perihepatic, meaning it consists of tumor deposits on the liver’s surface (its capsule) from peritoneal seeding. True liver parenchymal metastases, tumors that grow inside the liver tissue itself, are much less common and generally represent blood-borne spread rather than peritoneal seeding. A study of 244 patients with serous ovarian cancer found that blood-borne liver metastases were associated with shorter survival, while surface-level invasion from peritoneal disease did not independently worsen outcomes and behaved prognostically like peritoneal disease elsewhere.

¹²

CT imaging can help distinguish the two types, which influences surgical planning. Surface deposits may be resectable as part of a comprehensive debulking operation, whereas multiple deep liver metastases generally indicate a more systemic disease pattern that changes the treatment approach.

¹³

Splenic involvement follows a similar surface-versus-deep distinction. Capsular deposits on the spleen from peritoneal seeding are relatively common in advanced disease, but true intraparenchymal splenic metastases from blood-borne spread are rare enough to warrant case reports.

¹⁴

Lymph Node Metastasis

While transcoelomic spread dominates, ovarian cancer also spreads through lymphatic channels to pelvic and para-aortic lymph nodes. How often this occurs depends heavily on the tumor subtype and stage. A large population-based analysis found that lymph node metastasis was present in about 12% of lower-grade (type I) ovarian cancers and roughly 37% of higher-grade (type II) tumors overall. Within each group, rates climbed sharply with advancing local stage: for high-grade tumors, about 6% at early local stage, rising to over 60% in patients with distant metastatic disease.

¹⁵

Under the current staging system, retroperitoneal lymph node metastasis places the patient in stage III even if the disease has not visibly spread across the peritoneum. Extra-abdominal lymph node involvement, such as in the groin or above the diaphragm, pushes the staging to IV.

¹⁶

Brain Metastases

Brain metastases from ovarian cancer are uncommon but not as vanishingly rare as once thought. A large registry-based study found brain involvement in about 0.3% of all ovarian cancer patients and roughly 12% of those with metastatic disease. The median survival after a brain metastasis diagnosis was only about two months, though this figure reflects a mix of patients including those who received no treatment.

¹⁷

A multicenter retrospective study of 129 patients with ovarian cancer brain metastases found that the median gap between the original cancer diagnosis and the brain metastasis was about 26 months. The cerebellum and brainstem were the most frequent sites within the brain, followed by the frontal lobe. Headache was the most common presenting symptom, occurring in about half of patients, with paralysis or weakness in about 18%. High-grade serous ovarian cancer and BRCA mutations are emerging as risk factors for brain spread.

¹⁸¹⁹

Bone, Skin, and Other Unusual Sites

Bone metastases from ovarian cancer are rare. When they do occur, the vertebrae, pelvic bones, and skull are the most commonly affected sites, and the lesions tend to be osteolytic, meaning they break down bone rather than building it up.

²⁰

Skin metastases are rarer still, reported in roughly 1% to 4% of patients. The best-known form is the Sister Mary Joseph nodule, a metastatic deposit that appears at the umbilicus (belly button). Ovarian cancer is the most common cause of this nodule in women. The nodule is typically firm, irregular, and roughly 1 to 1.5 centimeters in size, though it can grow much larger. Because it can mimic benign conditions like a hernia or a cyst, it sometimes goes unrecognized until biopsy.

²¹²²

In some cases, a Sister Mary Joseph nodule is the first clinical sign of an underlying malignancy, making it a potentially important diagnostic clue that should prompt further investigation.

²³

How Staging Captures the Spread Pattern

The FIGO staging system for ovarian cancer was redesigned in 2014 to better reflect these metastatic patterns. Stage III encompasses disease that has spread across the abdominal peritoneum outside the pelvis or into retroperitoneal lymph nodes. Stage IV is reserved for disease that has moved beyond the peritoneal cavity entirely. Specific criteria for stage IV include pleural effusion with positive cytology, liver or splenic parenchymal metastases (not just surface deposits), metastases to extra-abdominal organs, and transmural bowel involvement.

²⁴

The distinction between stage III and IV is not just academic. It influences whether a patient is offered upfront surgery, chemotherapy first, or a combination approach. It also shapes the imaging workup. Whole-body MRI with diffusion-weighted sequences has shown higher accuracy for peritoneal staging (about 91%) compared with CT (about 75%) or PET/CT (about 71%) in feasibility studies, though CT remains the most widely available and commonly used first-line tool.

²⁵

Surgical Implications of Where Disease Has Spread

Because ovarian cancer predominantly spreads across peritoneal surfaces rather than deep into organs, surgery plays an unusually central role in treatment, even for advanced disease. The goal of cytoreductive or “debulking” surgery is to remove every visible tumor implant. When surgeons achieve complete cytoreduction, with no residual visible disease, outcomes improve substantially. The Peritoneal Cancer Index, a scoring system that maps tumor burden across 13 abdominal regions, helps predict whether complete removal is achievable. In patients who receive chemotherapy before surgery, a reduction of at least 8 to 9 points in that score was a better predictor of complete surgical clearance than simply reaching a low absolute score.

²⁶

In a randomized trial, patients who received heated chemotherapy bathed directly into the abdominal cavity (HIPEC) during surgery had a median overall survival of about 46 months, compared with roughly 34 months for those who had surgery alone. Recurrence-free survival also improved, from about 11 months to about 14 months.

²⁷

HIPEC works in part because the disease it targets is peritoneal rather than blood-borne: a heated chemotherapy wash can physically contact tumor cells on exposed surfaces, which would be impossible if the cancer were embedded deep in the liver or lungs. The peritoneal-dominant pattern of ovarian cancer metastasis is precisely what makes this approach feasible.

Bowel Obstruction as a Consequence of Peritoneal Spread

One of the most distressing consequences of extensive peritoneal disease is malignant bowel obstruction. When tumor implants coat the surface of the intestines, they can compress or infiltrate the bowel wall, blocking the passage of food and fluid. In recurrent ovarian cancer, bowel obstruction is not usually a one-time event. Research has found that patients in this situation experienced a median of three episodes of obstruction before death, with short intervals between episodes, suggesting it becomes more of a chronic state than an isolated complication.

²⁸

Management of malignant bowel obstruction in this setting is often palliative, focused on comfort and quality of life. Options include medications to reduce intestinal secretions, venting gastrostomy tubes to relieve pressure, and sometimes surgical bypass, though reoperation carries significant risk in patients with widespread peritoneal disease. The location and pattern of bowel involvement, whether it is a single point of obstruction or diffuse coating of multiple loops, determines which of these approaches is most appropriate.

Laying Hens and the Search for Prevention Models

An unexpected corner of ovarian cancer research involves domestic chickens. Laying hens develop spontaneous ovarian tumors at high rates, and these tumors share striking similarities with human ovarian cancer in terms of histology, staging, and metastatic pattern, including peritoneal spread. This has made hens a valuable preclinical model for studying how ovarian cancer arises and spreads, and for testing preventive interventions, something that is nearly impossible to study in humans because the disease is typically caught only after it has already metastasized.

²⁹

Researchers have used the hen model to study whether dietary or hormonal interventions can slow tumor initiation or peritoneal dissemination. The appeal is straightforward: hens develop the disease spontaneously, within a manageable timeframe, and their tumors behave like the human version. It is one of the few animal models where you can study the full natural progression of ovarian cancer, from primary tumor to peritoneal metastasis, without having to artificially inject cancer cells.